← Back to Search

Local Anesthetic

Tumescent Lidocaine with liposuction for Anesthesia (TLA Trial)

Phase 1 & 2
Waitlist Available
Led By Jeffrey A Klein, MD
Research Sponsored by Klein, Jeffrey A., M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights

TLA Trial Summary

This pharmacokinetic clinical trial is a dose ranging study of lidocaine in tumescent local anesthesia. The goal is to understand the absorption pharmacokinetic of tumescent lidocaine and to determine an objective (statistical) estimate of the maximum safe mg/kg dosage of lidocaine in tumescent local anesthesia without liposuction.

TLA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Peak or maximum serum lidocaine concentration (Cmax) following a given mg/kg dosage of lidocaine delivered by subcutaneous infiltration of tumescent local anesthesia
Secondary outcome measures
Cmax following 45mg/kg tumescent lidocaine has a Normal distribution. We define the probability that Cmax exceeds 6 microgram/ml, the toxic threshold for lidocaine as a function of lidocaine dosage.

TLA Trial Design

2Treatment groups
Experimental Treatment
Group I: Tumescent Lidocaine with liposuctionExperimental Treatment2 Interventions
Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction
Group II: Tumescent Lidocaine No LiposuctionExperimental Treatment2 Interventions
Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liposuction
2020
Completed Phase 2
~930

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Klein, Jeffrey A., M.D.Lead Sponsor
4 Previous Clinical Trials
633 Total Patients Enrolled
Jeffrey A Klein, MDPrincipal InvestigatorUniversity of Californiia, Riverside
1 Previous Clinical Trials
100 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Tumescent Lidocaine Maximum Safe mg/kg Dosage
2005. "Tumescent Lidocaine Maximum Safe mg/kg Dosage". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00977028.
All > Osa
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top